Giant cell tumor of bone: Epidemiological profile (fifth version) – A study protocol
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Outros Autores: | , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Research, Society and Development |
Texto Completo: | https://rsdjournal.org/index.php/rsd/article/view/33230 |
Resumo: | The giant cell tumor of bone (GCTB) represents approximately 5% of primary bone tumors, and more than half of cases affect individuals between 20 and 50 years of age. Despite being a benign neoplasm, 3 to 5% of cases may show pulmonary metastases, besides it has high potential for bone destruction at the main site of the lesion, often in the epiphyses of long bones, which may lead to serious functional problems in affected patients. Multidisciplinary treatment of GCTB has been a cause for discussion in the last decade due to the discovery of drugs such as denosumab that prevent tumor progression and may be useful in cases of patients with local recurrences and unresectable tumors. The therapeutic basis of GCTB remains the isolated surgical treatment by intralesional (with adjuvants), marginal or wide resection. Intralesional treatment presents higher rates of recurrence, however it preserves the adjacent joint function and much of the individual bone stock. Resection with wide margins presents lower recurrence rates but has shown worse functional results and frequent complications in bone reconstructions. Current knowledge of GCTB surgical outcomes has been based on major world series - there is a lack of Brazilian epidemiological and surgical data on this specific type of neoplasm, except for a few series of cases. The primary objective of this paper is to identify the epidemiological profile of GCTB; the secondary objectives are to describe the surgical aspects in the main diagnostic centers and treatment of bone tumors, to analyze the clinical and surgical aspects of patients with GCTB of wrist and hand, and to analyze the clinical and surgical aspects of patients with knee GCTB. These findings may help in the maintenance or change of national guidelines for the treatment of GCTB. This study protocol was submitted to ethical assessment under the CAAE (Ethical Appreciation Presentation Certificate) registry No. 94280918.0.0000.5327 (5th version), evaluated through the substantiated opinion No. 4.770.705, and approved by the Institutional Research Ethics Committee on June 12, 2022. |
id |
UNIFEI_f24ba0ece6631f33cd3fa9188812afe6 |
---|---|
oai_identifier_str |
oai:ojs.pkp.sfu.ca:article/33230 |
network_acronym_str |
UNIFEI |
network_name_str |
Research, Society and Development |
repository_id_str |
|
spelling |
Giant cell tumor of bone: Epidemiological profile (fifth version) – A study protocolTumor óseo de células gigantes: Perfil epidemiológico (quinta versión) - Un protocolo de estudioTumor de células gigantes do osso: Perfil epidemiológico (quinta versão) – Um protocolo de estudoBrazilDenosumabEpidemiologyGiant Cell Tumor of BoneMargins of ExcisionSurgical procedures, Operative.BrasilDenosumabEpidemiologiaTumor de Células Gigantes do OssoMargens de ExcisãoProcedimentos cirúrgicos operatórios.BrasilDenosumabEpidemiologíaTumor Óseo de Células GigantesMárgenes de EscisiónProcedimientos quirúrgicos operativos.The giant cell tumor of bone (GCTB) represents approximately 5% of primary bone tumors, and more than half of cases affect individuals between 20 and 50 years of age. Despite being a benign neoplasm, 3 to 5% of cases may show pulmonary metastases, besides it has high potential for bone destruction at the main site of the lesion, often in the epiphyses of long bones, which may lead to serious functional problems in affected patients. Multidisciplinary treatment of GCTB has been a cause for discussion in the last decade due to the discovery of drugs such as denosumab that prevent tumor progression and may be useful in cases of patients with local recurrences and unresectable tumors. The therapeutic basis of GCTB remains the isolated surgical treatment by intralesional (with adjuvants), marginal or wide resection. Intralesional treatment presents higher rates of recurrence, however it preserves the adjacent joint function and much of the individual bone stock. Resection with wide margins presents lower recurrence rates but has shown worse functional results and frequent complications in bone reconstructions. Current knowledge of GCTB surgical outcomes has been based on major world series - there is a lack of Brazilian epidemiological and surgical data on this specific type of neoplasm, except for a few series of cases. The primary objective of this paper is to identify the epidemiological profile of GCTB; the secondary objectives are to describe the surgical aspects in the main diagnostic centers and treatment of bone tumors, to analyze the clinical and surgical aspects of patients with GCTB of wrist and hand, and to analyze the clinical and surgical aspects of patients with knee GCTB. These findings may help in the maintenance or change of national guidelines for the treatment of GCTB. This study protocol was submitted to ethical assessment under the CAAE (Ethical Appreciation Presentation Certificate) registry No. 94280918.0.0000.5327 (5th version), evaluated through the substantiated opinion No. 4.770.705, and approved by the Institutional Research Ethics Committee on June 12, 2022.El tumor óseo de células gigantes (TOCG) representa aproximadamente el 5% de los tumores óseos primarios, y más de la mitad de los casos afectan a individuos entre 20 y 50 años. A pesar de ser una neoplasia benigna, del 3 al 5% de los casos pueden presentarse con metástasis pulmonares, además de tener un alto potencial de destrucción ósea en el sitio principal de la lesión, a menudo en las epífisis de los huesos largos, lo que puede conducir a problemas funcionales graves en los pacientes afectados. El tratamiento multidisciplinario de TOCG ha sido un tema de discusión en la última década debido al descubrimiento de fármacos, como el denosumab, que previenen la progresión tumoral y pueden ser útiles en casos de pacientes con recurrencias locales y tumores no resecables. La base terapéutica de la TOCG sigue siendo el tratamiento quirúrgico aislado por resección intralesional (con adyuvantes), marginal o amplio. El tratamiento intralesional presenta tasas de recurrencia más altas, pero preserva la función articular adyacente y gran parte del stock óseo individual. La resección con márgenes amplios tiene tasas de recurrencia más bajas, pero ha mostrado peores resultados funcionales y complicaciones frecuentes en las reconstrucciones óseas. El conocimiento actual de los resultados quirúrgicos de TOCG se ha basado en grandes series mundiales: faltan datos epidemiológicos y quirúrgicos brasileños sobre este tipo específico de neoplasia, con la excepción de algunas series de casos. El objetivo principal de este trabajo es identificar el perfil epidemiológico del TOCG; los objetivos secundarios son describir los aspectos quirúrgicos en los principales centros de diagnóstico y tratamiento de tumores óseos, analizar los aspectos clínicos y quirúrgicos de los pacientes con TOCG de puño y mano, y analizar los aspectos clínicos y quirúrgicos de los pacientes con TOCG de rodilla. Estos hallazgos pueden ayudar a mantener o cambiar las pautas nacionales para el tratamiento del TOCG. Este protocolo de estudio fue sometido a evaluación ética bajo el CAAE (Certificado de Presentación de Apreciación Ética) N. º 94280918.0.0000.5327 (5.ª versión), evaluado a través de la opinión incorporada N.º 4.770.705, y aprobado por el Comité de Ética de Investigación de la Institución el junio 12, 2021.O tumor de células gigantes do osso (TCGO) representa aproximadamente 5% dos tumores ósseos primários, e mais da metade dos casos afetam indivíduos entre 20 e 50 anos de idade. Apesar de ser uma neoplasia benigna, 3 a 5% dos casos podem apresentar metástases pulmonares, além de possuir alto potencial de destruição óssea no sítio principal da lesão, muitas vezes nas epífises de ossos longos, o que pode levar a sérios problemas funcionais nos pacientes afetados. O tratamento multidisciplinar do TCGO tem sido motivo de discussão na última década devido à descoberta de medicamentos, como o denosumab, que previnem a progressão do tumor e podem ser úteis em casos de pacientes com recidivas locais e tumores não ressecáveis. A base terapêutica do TCGO permanece sendo o tratamento cirúrgico isolado por ressecção intralesional (com adjuvantes), marginal ou ampla. O tratamento intralesional apresenta maiores taxas de recidiva, porém preserva a função articular adjacente e grande parte do estoque ósseo individual. A ressecção com margens amplas apresenta menores taxas de recorrência, mas tem mostrado piores resultados funcionais e complicações frequentes nas reconstruções ósseas. O conhecimento atual dos desfechos cirúrgicos do TCGO tem sido baseado em grandes séries mundiais - faltam dados epidemiológicos e cirúrgicos brasileiros sobre esse tipo específico de neoplasia, com exceção de algumas séries de casos. O principal objetivo deste trabalho é identificar o perfil epidemiológico do TCGO; os objetivos secundários são descrever os aspectos cirúrgicos nos principais centros de diagnóstico e tratamento de tumores ósseos, analisar os aspectos clínicos e cirúrgicos dos pacientes com TCGO de punho e mão e analisar os aspectos clínicos e cirúrgicos dos pacientes com TCGO do joelho. Esses achados podem ajudar na manutenção ou mudança de diretrizes nacionais para o tratamento da TCGO. Este protocolo de estudo foi submetido à apreciação ética sob o registro CAAE (Certificado de Apresentação de Apreciação Ética) N. º 94280918.0.0000.5327 (5.ª versão), avaliado através do parecer consubstanciado N. º 4.770.705, e aprovado pelo Comitê de Ética em Pesquisa Institucional em 12 de junho de 2021.Research, Society and Development2022-08-09info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/3323010.33448/rsd-v11i10.33230Research, Society and Development; Vol. 11 No. 10Research, Society and Development; Vol. 11 Núm. 10Research, Society and Development; v. 11 n. 102525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIenghttps://rsdjournal.org/index.php/rsd/article/view/33230/28056Copyright (c) 2022 Ricardo Gehrke Becker; Bruno Antunes Pereira; Carlos Roberto Galia; Otavio Pereira Cadore; Bruno Führ; Julie Francine Cerutti Santos Pestilho; Carlos Alberto Souza Macedo; Willian Bernardo Spechet Rabusxke; Eduardo da Silva Rodrigues; Alex Guedeshttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessBecker, Ricardo Gehrke Pereira, Bruno Antunes Galia, Carlos Roberto Cadore, Otavio Pereira Führ, Bruno Pestilho, Julie Francine Cerutti SantosMacedo, Carlos Alberto Souza Rabusxke, Willian Bernardo Spechet Rodrigues, Eduardo da SilvaGuedes, Alex2022-08-12T22:23:03Zoai:ojs.pkp.sfu.ca:article/33230Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:48:56.782831Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false |
dc.title.none.fl_str_mv |
Giant cell tumor of bone: Epidemiological profile (fifth version) – A study protocol Tumor óseo de células gigantes: Perfil epidemiológico (quinta versión) - Un protocolo de estudio Tumor de células gigantes do osso: Perfil epidemiológico (quinta versão) – Um protocolo de estudo |
title |
Giant cell tumor of bone: Epidemiological profile (fifth version) – A study protocol |
spellingShingle |
Giant cell tumor of bone: Epidemiological profile (fifth version) – A study protocol Becker, Ricardo Gehrke Brazil Denosumab Epidemiology Giant Cell Tumor of Bone Margins of Excision Surgical procedures, Operative. Brasil Denosumab Epidemiologia Tumor de Células Gigantes do Osso Margens de Excisão Procedimentos cirúrgicos operatórios. Brasil Denosumab Epidemiología Tumor Óseo de Células Gigantes Márgenes de Escisión Procedimientos quirúrgicos operativos. |
title_short |
Giant cell tumor of bone: Epidemiological profile (fifth version) – A study protocol |
title_full |
Giant cell tumor of bone: Epidemiological profile (fifth version) – A study protocol |
title_fullStr |
Giant cell tumor of bone: Epidemiological profile (fifth version) – A study protocol |
title_full_unstemmed |
Giant cell tumor of bone: Epidemiological profile (fifth version) – A study protocol |
title_sort |
Giant cell tumor of bone: Epidemiological profile (fifth version) – A study protocol |
author |
Becker, Ricardo Gehrke |
author_facet |
Becker, Ricardo Gehrke Pereira, Bruno Antunes Galia, Carlos Roberto Cadore, Otavio Pereira Führ, Bruno Pestilho, Julie Francine Cerutti Santos Macedo, Carlos Alberto Souza Rabusxke, Willian Bernardo Spechet Rodrigues, Eduardo da Silva Guedes, Alex |
author_role |
author |
author2 |
Pereira, Bruno Antunes Galia, Carlos Roberto Cadore, Otavio Pereira Führ, Bruno Pestilho, Julie Francine Cerutti Santos Macedo, Carlos Alberto Souza Rabusxke, Willian Bernardo Spechet Rodrigues, Eduardo da Silva Guedes, Alex |
author2_role |
author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Becker, Ricardo Gehrke Pereira, Bruno Antunes Galia, Carlos Roberto Cadore, Otavio Pereira Führ, Bruno Pestilho, Julie Francine Cerutti Santos Macedo, Carlos Alberto Souza Rabusxke, Willian Bernardo Spechet Rodrigues, Eduardo da Silva Guedes, Alex |
dc.subject.por.fl_str_mv |
Brazil Denosumab Epidemiology Giant Cell Tumor of Bone Margins of Excision Surgical procedures, Operative. Brasil Denosumab Epidemiologia Tumor de Células Gigantes do Osso Margens de Excisão Procedimentos cirúrgicos operatórios. Brasil Denosumab Epidemiología Tumor Óseo de Células Gigantes Márgenes de Escisión Procedimientos quirúrgicos operativos. |
topic |
Brazil Denosumab Epidemiology Giant Cell Tumor of Bone Margins of Excision Surgical procedures, Operative. Brasil Denosumab Epidemiologia Tumor de Células Gigantes do Osso Margens de Excisão Procedimentos cirúrgicos operatórios. Brasil Denosumab Epidemiología Tumor Óseo de Células Gigantes Márgenes de Escisión Procedimientos quirúrgicos operativos. |
description |
The giant cell tumor of bone (GCTB) represents approximately 5% of primary bone tumors, and more than half of cases affect individuals between 20 and 50 years of age. Despite being a benign neoplasm, 3 to 5% of cases may show pulmonary metastases, besides it has high potential for bone destruction at the main site of the lesion, often in the epiphyses of long bones, which may lead to serious functional problems in affected patients. Multidisciplinary treatment of GCTB has been a cause for discussion in the last decade due to the discovery of drugs such as denosumab that prevent tumor progression and may be useful in cases of patients with local recurrences and unresectable tumors. The therapeutic basis of GCTB remains the isolated surgical treatment by intralesional (with adjuvants), marginal or wide resection. Intralesional treatment presents higher rates of recurrence, however it preserves the adjacent joint function and much of the individual bone stock. Resection with wide margins presents lower recurrence rates but has shown worse functional results and frequent complications in bone reconstructions. Current knowledge of GCTB surgical outcomes has been based on major world series - there is a lack of Brazilian epidemiological and surgical data on this specific type of neoplasm, except for a few series of cases. The primary objective of this paper is to identify the epidemiological profile of GCTB; the secondary objectives are to describe the surgical aspects in the main diagnostic centers and treatment of bone tumors, to analyze the clinical and surgical aspects of patients with GCTB of wrist and hand, and to analyze the clinical and surgical aspects of patients with knee GCTB. These findings may help in the maintenance or change of national guidelines for the treatment of GCTB. This study protocol was submitted to ethical assessment under the CAAE (Ethical Appreciation Presentation Certificate) registry No. 94280918.0.0000.5327 (5th version), evaluated through the substantiated opinion No. 4.770.705, and approved by the Institutional Research Ethics Committee on June 12, 2022. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-08-09 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/33230 10.33448/rsd-v11i10.33230 |
url |
https://rsdjournal.org/index.php/rsd/article/view/33230 |
identifier_str_mv |
10.33448/rsd-v11i10.33230 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/33230/28056 |
dc.rights.driver.fl_str_mv |
https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Research, Society and Development |
publisher.none.fl_str_mv |
Research, Society and Development |
dc.source.none.fl_str_mv |
Research, Society and Development; Vol. 11 No. 10 Research, Society and Development; Vol. 11 Núm. 10 Research, Society and Development; v. 11 n. 10 2525-3409 reponame:Research, Society and Development instname:Universidade Federal de Itajubá (UNIFEI) instacron:UNIFEI |
instname_str |
Universidade Federal de Itajubá (UNIFEI) |
instacron_str |
UNIFEI |
institution |
UNIFEI |
reponame_str |
Research, Society and Development |
collection |
Research, Society and Development |
repository.name.fl_str_mv |
Research, Society and Development - Universidade Federal de Itajubá (UNIFEI) |
repository.mail.fl_str_mv |
rsd.articles@gmail.com |
_version_ |
1797052770065317888 |